New Pill Successfully Lowers Stubborn Blood Pressure and Protects Kidneys in High-Risk Patients

An experimental drug called baxdrostat has demonstrated promising results in a Phase 2 clinical trial by lowering blood pressure and potentially protecting kidney function in patients with chronic kidney disease (CKD) and uncontrolled hypertension. Published in the *Journal of the American Society of Nephrology*, the study involved 195 participants with an average systolic blood pressure of 151 mm Hg despite standard treatments like ACE inhibitors and angiotensin receptor blockers. The drug works by inhibiting aldosterone, a hormone linked to sodium retention, water buildup, and kidney damage. After 26 weeks, baxdrostat reduced systolic blood pressure by 8.1 mm Hg compared to a placebo and lowered urine albumin—a marker of kidney damage—by 55%. This suggests the drug may help delay kidney disease progression, though its safety profile includes elevated potassium levels, a known risk of medications affecting the renin-angiotensin-aldosterone system. The trial was led by Jamie P. Dwyer, M.D., a professor at the University of Utah Health. While baxdrostat has not yet been approved, its potential is being further tested in two large Phase 3 trials. The findings offer hope for millions struggling with CKD and hypertension, two conditions that often worsen each other in a dangerous cycle. Researchers noted that despite standard treatments, many participants still had uncontrolled blood pressure and kidney dysfunction. Baxdrostat’s ability to directly target aldosterone production may address these unmet needs. The drug’s development marks a potential breakthrough in managing high-risk cardiovascular and renal conditions, though long-term safety and efficacy will depend on ongoing studies.